Home > Back to Publisher > Report Information

Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities

PharmaVision
December 15, 2008
183 Pages - SKU: PBA2613354

Abstract Table of Contents Search inside this report Related Reports

This cutting edge & insightful report can be used to interpret & assess the potential of stem cell-based medicines. It provides opinions & market projections to:

assess the commercial potential of stem cell-based therapies in all of the key therapeutic areas: autoimmune diseases, cardiovascular, CNS & hematological malignancies;
identify key pharma & delivery specialists advancing the next generation of regenerative medicines;
gain an in-depth understanding of the technological manufacturing & delivery issues which face companies developing stem cell-based therapies;
evaluate the options available for delivering stem cell-based therapies now & in the future;
discover which companies are tackling the technological hurdles & are in a prime position to exploit new opportunities;
analyzes how the market will evolve over the next decade highlighting key trends, opportunities & challenges.

Key Findings: Stem Cells & Cell-Based Delivery; The Market for Stem Cell-Based Therapies; Stem Cell-Based Therapies for Cardiovascular Disease; Stem Cell-Based Therapies for CNS Disorders; Stem Cell Therapies for Diabetes; Stem Cell Therapies for Cancer; Stem Cell-Based Therapeutics: Challenges & Opportunities; Future of Stem Cell-Based Therapeutics & Market Trends
Chapter 1 Stem Cells & Cell-Based Delivery: Key Points; Introduction; An introduction to stem cell science; Embryonic stem cells; Adult stem cells; Creating pluripotent cells from adult tissue; Nuclear transfer/therapeutic cloning; Combining embryonic stem cell therapy with gene therapy; Stem cell therapy - a discovery timeline; Major scientific challenges for the development of stem cell therapies; Report structure
Chapter 2 Stem Cell-Based Therapies: Pipeline Analysis: Key Points; Key therapy areas covered by stem cell-based therapies; Product pipelines; Stem cells for drug discovery; Stem cell culture, expansion and manufacturing; Stem cell companies analysed in this report
Chapter 3 Stem Cell-Based Therapies for Cardiovascular Disease: Key Points; Introduction; Autologous cell platforms; Case Study: MyoCell (Bioheart Inc); Case Study: Myoblast (Advanced Cell Technology); Case study: CardioCure (Gamida Cell Ltd); Case Study: C-Cure (Cardio3 BioSciences); Case Study: Celution System (Cytori Therapeutics); Allogeneic cell platforms; Mesenchymal stem cell therapies; Case Study: Prochymal (Osiris Therapeutics); Case study: Revascor? (Angioblast Systems Inc); Case study: PLX-PAD (Pluristem Therapeutics Inc); Human embryonic stem cell therapies; Case Study: ACT Cellerate (Advanced Cell Technology); Cell delivery technologies; Our opinion on stem cell-derived therapies for CV diseases; Where the technology is now, its evolution, achievements and pitfalls; Competition; Potential future applications; Activity in the market; Major players; Winners
Chapter 4 Stem Cell-Based Therapies for CNS Diseases: Points; Introduction; Autologous cell platforms; Case Study: NurOwn (BrainStorm Cell Therapeutics Inc); Case study: NeuroGeneration; Allogeneic cell platforms; Stem cells from donated tissue; Case Study: HuCNS-SC® (StemCells Inc); Case Study: ReNeuron; Case Study: Neuralstem; Case study: Q-cells (Q Therapeutics Inc); Case study: StemedicaMCT (Stemedica USA and Stemedica International); Stem cells from umbilical cord blood; Case study: Beike Biotechnology; Human embryonic stem cells; Case Study: GRNOPC1 (Geron); Case study: hESCs from California Stem Cell Inc; Cell delivery technologies; Our opinion on stem cell-based therapies for CNS diseases; Where the technology is now, its evolution, achievements and pitfalls; Competition; Potential future applications; Activity in the market
Chapter 5 Stem Cell-Based Therapies for Autoimmune, Inflammatory & Other conditions: Key Points; Introduction; Crohn’s disease; Case study: Prochymal for Crohn’s disease (Osiris); Case Study: Ontaril (Cellerix); Diabetes; Autologous stem cell transplants for diabetes; Allogeneic stem cell transplants for diabetes; Osteoarthritis; Lung diseases; Chronic obstructive pulmonary disease; Pulmonary arterial hypertension; Our opinion on stem cell-based therapies for autoimmune and other diseases; Where the technology is now, its evolution, achievements and pitfalls; Competition; Potential future applications; Major players and winners
Chapter 6 Stem Cell-Based Therapies for Graft versus Host Disease, Hematological Malignancies and Cancer: Key Points; Introduction; Cancer stem cells; Stem cells as a delivery vehicle; Graft versus host disease; Expanded umbilical cord blood transplants for malignant diseases; Case Study: StemEx (Gamida Cell); Stem cells as delivery systems; Lung cancer; Metastatic cancer and intracranial tumors; Hematological malignancy; Multi-lineage progenitor cells (BioE); Conclusion; Our opinion on stem cell-derived therapies for GvHD, hematological malignancies and cancer; Where the technology is now, its evolution, achievements and pitfalls; Competition; Potential future applications; Activity in the market, major players and winners
Chapter 7 Challenges & Opportunities for Stem Cell-Based Therapies: Key Points; Introduction; Ethical issues for stem cell research; Funding stem cell research; Intellectual property; Manufacturing stem cell-based products; Regulation; Reimbursement; Delivering stem cell-based therapies and tissue engineering; Challenges; Opportunities
Chapter 8 Market size, Evolution & Prospects: Key Points; Key stem cell therapy companies; Recent deals and alliances; The global stem cell market 2008-2014; Analysis parameters; Market forecast 2008-2014; Global stem cell-based therapy market in 2020; Drivers and market trends; Summary & Conclusions; Acknowledgements; Bibliography & Endnotes
List of Figures: Figure 1: Source of embryonic stem cells: the blastocyst; Figure 2: Differentiation of embryonic stem cells; Figure 3: Somatic cell nuclear transfer; Figure 4: Combining gene therapy and cell therapy for sickle cell anaemia in a mouse model; Figure 5: Stem cell research: a timeline; Figure 6: Stem cell therapeutics: defining therapeutic areas; Figure 7: Number of projects in the different stages of pharmaceutical development; Figure 8: Number of projects in each therapeutic area, by stage of development; Figure 9: Proportions of autologous and allogeneic technology platforms; Figure 10: Stem cell sources (embryonic, adult or cord blood/placenta); Figure 11: MyoCell: Heart failure treatment process; Figure 12: Advanced Cell Technologies Myoblast Phase 1 programme; Results; Figure 13: The Celution system from Cytori Therapeutics; Figure 14: Preclinical data demonstrating the effects of Prochymal therapy on the heart; Figure 15: PLX cells growing in Pluristem’s PluriX™ bioreactor; Figure 16: ACTCellerate Technology; Figure 17: Schematic of cell-based therapy administration to the myocardium; Figure 18: Cells affected by different CNS diseases/disorders; Figure 19: NeuroGeneration’s Parkinson’s disease therapy; Figure 20: StemCells Inc technology platform; Figure 21: ReNeuron’s process for generating therapeutic cells; Figure 22: Stemedica’s established cell lines; Figure 23 Results of animal studies with Geron’s oligodendroglial progenitorcells derived from human ESCs; Figure 24: Stem cell sources under investigation to treat type 1 diabetes; Figure 25: Stem cells applications in cancer and other malignant diseases; Figure 26: Strategies for potentiating stem cells for tumor treatment; Figure 28: Challenges and opportunities for stem cell science; Figure 29: Ethical issues with stem cells from different sources; Figure 30: Federal funding of embryonic stem cell research in the US: a timeline; Figure 31: US patent ownership in the stem cell field; Figure 32: Stem cell-based therapeutics: market drivers
List of Tables: Table 1: Pros and cons of different stem cell types; Table 2: Diseases targeted by stem cell-based therapeutics; Table 3: Stem cell therapy companies discussed in this report; Table 4: Leading companies evaluating stem cell-based CV therapies; Table 5: Leading academic institutions researching the use of stem cells to treat CV diseases; Table 6: Leading companies evaluating stem cell-based therapies for CNS diseases; Table 7: Leading institutes evaluating stem cell-based therapies for CNS diseases; Table 8: Geron’s stem cell-based product pipeline; Table 9: Leading companies evaluating stem cell therapies for autoimmune and other diseases; Table10: Leading academic institutes evaluating stem cell therapies for autoimmune and other diseases; Table 11: Leading companies evaluating stem cell therapies for GvHD and hematological malignancies; Table 12: Academic institutions with an interest in GvHD, hematological malignancies and cancer; Table 13: Other clinical trials of mesenchymal stem cells for the prevention or treatment of GVHD; Table 14: Results of Phase 1/2 trial for StemEx; Table 15: Global positions on research on embryonic stem cells derived from IVF procedures; Table 16: Current funds available from individual US states for embryonic and adult stem cell research; Table 17: Summary of leading stem cell-based therapeutics companies; Table 18: Recent licensing deals and alliances with big pharma/biotech; Table 19: Stem cell-based therapies included in the market forecast; Table 20: Forecast of pipeline stem cell therapy products 2008-2014 (US$m); Table 21: Forecast of pipeline stem cell therapy products 2015-2020 (US$m)

Stem Cell-Based Therapeutic Delivery: Challenges & Opportunities

Share this report

Other tasks

Research Assistance

Related Markets

Stem Cell Reports

Free Alert Me service